Human Prescription Drug and Biological Products — Labeling for Dosing Based on Weight or Body Surface Area for Ready-to-Use Containers — “Dose Banding”; Draft Guidance for Industry

About this resource:

Non-Systematic Review

Source: Food and Drug Administration

Last Reviewed: 2022

“Dose banding” uses pre-defined ranges (“bands”) of a patient’s weight or body surface area to calculate the appropriate dose of a medicine. Some medicines, like infusions for chemotherapy treatment, are manufactured in ready-to-use containers that are available in different strengths. In this draft guidance, the U.S. Food and Drug Administration (FDA) offers recommendations for drug manufacturers wanting to include information about dose banding on medicine labels. This guidance applies to:

  • New drug applications submitted under the Federal Food, Drug, and Cosmetic Act 
  • Biologics license applications submitted under the Public Health Service Act 
  • Supplements to an approved application
Read more about this resource

Objectives related to this resource (1)

Suggested Citation

1.

Food and Drug Administration. (2022). Human Prescription Drug and Biological Products — Labeling for Dosing Based  on Weight or Body Surface Area for  Ready-to-Use Containers — “Dose  Banding”; Draft Guidance for Industry. Retrieved from https://www.fda.gov/regulatory-information/search-fda-guidance-documents/human-prescription-drug-and-biological-products-labeling-dosing-based-weight-or-body-surface-area.